Biogen Inc. ($BIIB) Stock Forecast: Down 2.5% Today

What is Biogen Inc.?

BIIB (Biogen Inc.) is a biotechnology company specializing in neurological and neurodegenerative diseases. The biotech sector has experienced volatility recently, with companies encountering regulatory and legal obstacles.

Why is Biogen Inc. going down?

BIIB stock is down 2.5% on Feb 25, 2026 15:48

• The downward trend in BIIB's stock price today may be linked to a trade secrets lawsuit and a dismissal motion filed by Definium Therapeutics Inc., resulting in uncertainty and legal concerns.
• Market sentiment could also be influenced by the struggles of other biotech firms such as Avidity Biosciences, which reported significant financial losses, leading to doubts about the sector's financial performance and future growth.
• Furthermore, the FDA's rejection of Alvotech's biologics license application due to facility issues and the subsequent legal investigation could have raised apprehensions about regulatory challenges in the biotech industry, impacting attitudes towards companies like BIIB.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient

Definium Therapeutics Inc., a biotechnology company, has filed a motion to dismiss a trade secrets lawsuit brought by its former clinical trial vendor, Signant Health Holding Corp. Definium argues that Signant's claims, which allege improper sharing of confidential information, lack sufficient detail and legal support. The company also seeks to strike allegations regarding its Phase 3 trials, deeming them irrelevant and prejudicial.

https://usaherald.com/biotech-firm-developing-lsd-based-psychiatric-treatments-moves-to-dismiss-trade-secrets-lawsuit-calls-claims-by-former-clinical-trial-vendor-legally-deficient/

Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives

Avidity Biosciences (RNA) reported a net loss of US$237.1 million for FY 2025, bringing its trailing 12-month net loss to US$684.6 million against total revenue of US$18.8 million. While analysts forecast 51.4% annual revenue growth, challenging the current loss-making trend, critics point to expanding losses and a P/B ratio higher than the industry average. Despite a significant DCF fair value indicating undervaluation, the company faces skepticism regarding its path to profitability and shareholder dilution.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rna/avidity-biosciences/news/avidity-biosciences-rna-posts-fy-2025-us237-million-loss-cha

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

Supernus Pharmaceuticals, Inc. announced record total revenues of $211.6 million for Q4 2025 and $719.0 million for the full year 2025, marking increases of 21% and 9% respectively, driven by strong growth in its four key products, Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company has resumed new patient initiation for ONAPGO and provided a full-year 2026 guidance forecasting total revenues between $840 million and $870 million. These results reflect significant progress in strategic objectives, including the acquisition of Sage Therapeutics, Inc. and the launch of ONAPGO.

https://www.globenewswire.com/news-release/2026/02/24/3244038/0/en/Supernus-Announces-Record-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Stoke Therapeutics, Inc. announced that its CEO, Ian F. Smith, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company is a biotechnology firm known for its lead investigational medicine, zorevunersen, which is in development as a potential disease-modifying treatment for Dravet syndrome. A live audio webcast of the presentation will be available on Stoke's investor relations website.

https://www.businesswire.com/news/home/20260224160878/en/Stoke-Therapeutics-to-Present-at-the-TD-Cowen-46th-Annual-Health-Care-Conference

Alvotech (ALVO) Is Down 9.1% After FDA Rejects AVT05 Over Facility Issues and Legal Probe

Alvotech (ALVO) shares dropped 9.1% after the FDA rejected its AVT05 biologics license application due to facility inspection issues, leading to an investigation by Kirby McInerney LLP for potential securities law violations. This setback raises concerns about Alvotech's quality control and regulatory risk management, despite a recent patent settlement for AVT06 offering some future clarity. The company's investment narrative, centered on its biosimilar pipeline and partner network, is now being re-evaluated in light of these regulatory and legal challenges.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-alvo-is-down-91-after-fda-rejects-avt05-over-facili

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Biogen Inc. Price History

31.09.2025 - BIIB Stock was up 3.1%

• BIIB surpassed Q3 earnings and revenue expectations, leading to an initial decline in its stock price following the company's reduction of its 2025 EPS forecast.
• The approval from Health Canada for "LEQEMBI®" to treat early Alzheimer's disease likely contributed to the stock's positive movement.
• Analysts highlighting the potential of Biogen's long-term immunology pipeline, particularly after a recent licensing agreement, may have boosted investor confidence in the company.
• The stock's bullish performance can be attributed to a mix of strong financial results, favorable regulatory milestones, and promising developments in Biogen's product pipeline.

30.09.2025 - BIIB Stock was up 2.3%

• Biogen (BIIB) reported impressive Q3 earnings and revenues, surpassing estimates by a significant margin, indicating strong financial performance.
• Health Canada granting authorization for "LEQEMBI®" for the treatment of Early Alzheimer's Disease is a significant milestone for Biogen, boosting investor confidence in the company's Alzheimer's treatment pipeline.
• The licensing agreement with Vanqua Bio to acquire exclusive rights to a preclinical oral C5aR1 antagonist strengthens Biogen's immunology portfolio, highlighting the company's commitment to innovation and expansion in the healthcare sector.
• The positive news surrounding Biogen's financials, advancements in Alzheimer's treatment, and expansion of its immunology pipeline likely contributed to the bullish movement in the stock today.

06.01.2026 - BIIB Stock was up 2.4%

• BIIB stock surged today, hitting a 52-week high at $190.34, marking a 31.14% rise in the past year and a 43.31% gain in the last six months.
• The positive market response follows Biogen's strong Q4 2025 financial performance, surpassing revenue projections and beating analyst estimates for non-GAAP EPS.
• Biogen's strategic focus on its at-home Alzheimer’s drug, successful trial outcomes for multiple treatments, and receipt of FDA Breakthrough Therapy Designation have boosted investor confidence in the company's future growth prospects.
• Despite revenue challenges from declining multiple sclerosis treatments, Biogen's optimistic 2026 outlook, emphasis on neurodegenerative and rare diseases, and favorable valuation based on financial metrics have bolstered investor trust and fueled the stock's upward trajectory.

06.01.2026 - BIIB Stock was up 6.9%

• Biogen's stock demonstrated significant upward momentum, reaching a 52-week high, following the release of impressive fourth-quarter earnings and revenues, attributed to the notable sales growth of its Alzheimer's medication Leqembi.
• The company's strategic shift from a primary emphasis on multiple sclerosis to establishing itself as a key player in neuro-innovation, with successful treatments like Skyclarys and Leqembi, has amplified investor confidence and positively impacted the stock's performance.
• Biogen's perceived undervaluation, evidenced by a P/E ratio of 16.92 and a robust free cash flow yield of 8%, alongside favorable developments such as FDA recognitions and successful trial outcomes, has further bolstered the optimistic outlook surrounding the stock.
• Biogen's adept navigation of obstacles, including regulatory complexities and market competition, in conjunction with its growth-oriented approach through collaborations and a diversified product pipeline, highlights its potential for long-term success in the dynamic biopharmaceutical sector.

06.01.2026 - BIIB Stock was up 5.3%

• Despite a decrease in revenue from multiple sclerosis treatments, Biogen posted strong financial results for Q4 and full year 2025, thanks to growth products such as LEQEMBI, SKYCLARYS, and ZURZUVAE.
• Investors reacted positively to the company's overall performance and growth in newer products, leading to a bullish movement in the stock despite the decline in revenue from multiple sclerosis treatments.
• Biogen's emphasis on expanding its pipeline through acquisitions and collaborations, as well as achieving important regulatory milestones, has instilled optimism among investors despite challenges in its multiple sclerosis product portfolio.
• The market movement demonstrates investor trust in Biogen's capability to navigate competition, regulatory changes, and operational risks while fostering growth through innovative products and strategic initiatives.

25.01.2026 - BIIB Stock was down 2.5%

• The downward trend in BIIB's stock price today may be linked to a trade secrets lawsuit and a dismissal motion filed by Definium Therapeutics Inc., resulting in uncertainty and legal concerns.
• Market sentiment could also be influenced by the struggles of other biotech firms such as Avidity Biosciences, which reported significant financial losses, leading to doubts about the sector's financial performance and future growth.
• Furthermore, the FDA's rejection of Alvotech's biologics license application due to facility issues and the subsequent legal investigation could have raised apprehensions about regulatory challenges in the biotech industry, impacting attitudes towards companies like BIIB.

14.00.2026 - BIIB Stock was down 5.3%

• The downward movement in Biogen's stock is likely due to expected expenses in the fourth quarter related to in-process research and development (IPR&D) and milestone payments, impacting earnings per share.
• Despite introducing Leqembi and exploring new Alzheimer's treatments, the market response is pessimistic towards the predicted financial changes and costs.
• Analysts, including Bank of America Securities' Hold rating, may be influencing the bearish outlook as investors evaluate the company's financial prospects alongside its strategic goals and product advancements.

14.00.2026 - BIIB Stock was down 5.8%

• Biogen expects a significant impact on its fourth-quarter earnings per share due to in-process research and development (IPR&D) charges, leading to a negative investor sentiment.
• Analysts from Bank of America Securities and other firms hold mixed views on Biogen, resulting in differing ratings and price targets that have added to the uncertainty surrounding the stock.
• The European Commission's approval of a high-dose SPINRAZA regimen for spinal muscular atrophy has the potential to strengthen Biogen's investment outlook. However, concerns about managing pricing pressures on high-cost therapies may have influenced the stock negatively.
• The market's response to Biogen's financial adjustments and upcoming drug launches underscores the need to balance innovation with financial performance in the biotech sector, impacting investor sentiment and stock movement.

14.00.2026 - BIIB Stock was down 6.0%

• Today's downturn in BIIB stock is linked to an anticipated impact of about $1.26 per share on earnings due to research and development charges in the fourth quarter.
• Despite efforts to enhance its presence in the Alzheimer's market with product launches and research endeavors, the financial adjustments appear to have dampened investor confidence.
• Contributing to the bearish sentiment could be analyst ratings like the Hold recommendation from Bank of America Securities, creating uncertainty among investors due to varying opinions.
• The stock's negative performance today reflects a market reaction influenced by financial implications and analyst assessments, despite Biogen's ongoing advancements in its pipeline and infrastructure.

06.00.2026 - BIIB Stock was up 5.8%

• BIIB stock surged as Bank of America Securities reiterated a Hold rating with a price target of $189.00, indicating stability and potential growth.
• Anticipation of regulatory progress in international markets, especially in China, for their Alzheimer's treatment formulations, like Leqembi, contributed to the positive market sentiment.
• The acceptance of the Biologics License Application for the subcutaneous formulation of LEQEMBI® for early Alzheimer's disease in China by the National Medical Products Administration was a significant catalyst for the stock's rise.
• The market's positive reaction reflects investors' optimism towards BIIB's innovative treatments and potential expansion into new markets, such as China, driving the stock's bullish movement.

01.09.2025 - BIIB Stock was up 5.1%

• BIIB stock showed significant growth in trading today.
• The approval of "LEQEMBI®" for Early Alzheimer's Disease treatment in China is believed to have influenced the positive market sentiment.
• Although they received a Complete Response Letter from the FDA for a different drug application, the initiation of bullish coverage by analysts may have outweighed this development.
• Favorable analyst coverage and optimistic forecasts for Biogen likely boosted investor confidence and contributed to the stock's upward trajectory.

10.11.2025 - BIIB Stock was down 5.1%

• Biogen's stock saw a bearish trend despite receiving Health Canada authorization for ZURZUVAE, a groundbreaking treatment for postpartum depression. This unexpected market reaction could be due to various factors:
• The after-hours rally in other biotech stocks, driven by new clinical data and FDA designations, might have shifted investor focus away from Biogen temporarily.
• Highlighting Biogen's undervaluation and potential as a bargain could have already been priced in, leading to profit-taking by investors.
• The market might be reacting to the broader sector movements and investor sentiment rather than solely focusing on Biogen's individual achievements in the postpartum depression treatment space.
• Overall, despite the positive news regarding ZURZUVAE, external factors and profit considerations could have influenced the bearish movement in Biogen's stock today.